Systemic Therapy for Unresectable Stage III or Metastatic Cutaneous Melanoma

This is a clinical practice guideline for adults over the age of 18 years with unresectable stage III and stage IV cutaneous melanoma, without involvement of the central nervous system (CNS). The guideline reviews the use of BRAF biomarker testing, and provides recommendations for first- and second-line systemic therapy options. BRAF Inhibitors, MEK inhibitors, immune checkpoint Inhibitors, other biological agents (e.g. imatinib and bevacizumab), and chemotherapy agents are reviewed.